Global Search

Hide Filters

Showing 1489 results

Press release / Jun 02, 2023

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
Press release / May 31, 2024

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.…
Ad hoc release / Sep 17, 2024

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
Press release / Apr 25, 2017

Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued

Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
Press release / Apr 19, 2018

Novartis delivered a strong first quarter and acted to become a more focused medicines company

Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong…
IgA nephropathy
Press release / Oct 24, 2017

Novartis delivered growth on top and bottom line in all divisions in Q3

Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew…
Press release / Apr 23, 2015

Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio

Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)…
Press release / Jul 19, 2016

Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects

Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…